April 08, 2022
The Patent Trial and Appeal Board has agreed to review a Seagen Inc. antibody patent after the board previously used its discretion to reject two challenges from Daiichi Sankyo Inc. and AstraZeneca while a Texas federal jury on Friday found Daiichi willfully infringed the patent to the tune of $41.8 million.
June 25, 2021
The Patent Trial and Appeal Board said it won't review a Seagen Inc. cancer drug delivery patent being challenged by Daiichi Sankyo Inc. and AstraZeneca, noting that the drugmakers offered few assurances that they won't pursue the same invalidity arguments in parallel district court litigation.